Related Experiment Videos
Kinetics of carbamazepine and its 10,11-epoxide metabolite in children
Insights
Carbamazepine (CBZ) levels in children were similar to adults, with dose-concentration correlation weak in single-drug therapy. Combined anticonvulsant treatment altered CBZ and its epoxide metabolite levels.
Area of Science:
- Pharmacology
- Pediatric Neurology
- Clinical Pharmacy
Background:
- Carbamazepine (CBZ) is a widely used antiepileptic drug.
- Understanding CBZ pharmacokinetics in children is crucial for effective treatment.
- The role of its active metabolite, carbamazepine-10,11-epoxide (CBZ-epoxide), requires further investigation in pediatric populations.
Purpose of the Study:
- To assess plasma steady-state concentrations of carbamazepine (CBZ) and its metabolite (CBZ-epoxide) in children treated with CBZ.
- To investigate the relationship between CBZ dose and plasma concentration in pediatric patients.
- To compare CBZ and CBZ-epoxide levels in children on monotherapy versus polytherapy.
Main Methods:
- Plasma samples were collected from 43 children (aged 2-15 years) undergoing CBZ treatment.
- Twenty children received concomitant anticonvulsant medications.
- Plasma concentrations of CBZ and CBZ-epoxide were measured and analyzed.
Main Results:
- Plasma CBZ and CBZ-epoxide concentrations in children were comparable to those reported in adults.
- A weak correlation between CBZ dose and plasma concentration was observed in children on monotherapy; no correlation was found in polytherapy.
- Children on combined treatment exhibited lower CBZ levels and a higher proportion of CBZ-epoxide relative to the parent drug.
Conclusions:
- Pediatric CBZ plasma concentrations are similar to adults, but dose-response relationships differ, especially with polytherapy.
- The active metabolite CBZ-epoxide plays a significant role and its levels are influenced by concomitant anticonvulsant use.
- Monitoring both CBZ and CBZ-epoxide plasma concentrations is recommended for optimizing therapy and understanding the level-effect relationship in children due to interindividual variability.
Abstract:
The plasma steady-state concentration of carbamazepine (CBZ) and its metabolite (carbamazepine-10,11-epoxide, CBZ-epoxide) was assessed in 43 children (2-15 yr) on CBZ (Tegretol) treatment. Twenty of the children received combined treatment with other anticonvulsant drugs simultaneously. The plasma concentrations were in the same range as had been found in adult patients on corresponding doses. Only a weak correlation was noted between dose and plasma CBZ concentration in the group of children on single-drug treatment, and there was no correlation in the group of children on combined drug regimen. Plasma levels of CBZ correlated with those of the metabolite. Children on combined treatment had lower CBZ concentration and, expressed as percent of the parent drug, the metabolite concentration was significantly higher than in children treated only with CBZ. In 2 children the plasma half-life of CBZ was estimated and found to be slightly shorter than has previously been reported in adults. In evaluating the plasma level-effect relationship of CBZ, the plasma concentration of the CBZ-epoxide should be measured simultaneously because of its anticonvulsant effect and interindividual variability.